Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | EQ |
---|---|---|
09:32 ET | 156 | 0.68 |
09:36 ET | 150 | 0.6801 |
09:41 ET | 365 | 0.701 |
09:45 ET | 499 | 0.6801 |
09:48 ET | 103 | 0.6801 |
09:59 ET | 100 | 0.68 |
10:08 ET | 4200 | 0.680101 |
10:10 ET | 8304 | 0.6801 |
10:15 ET | 100 | 0.68 |
10:28 ET | 12768 | 0.6499 |
11:11 ET | 1700 | 0.6884 |
11:13 ET | 654 | 0.688 |
11:15 ET | 250 | 0.6876 |
11:36 ET | 2900 | 0.6871 |
11:40 ET | 100 | 0.6684 |
12:03 ET | 100 | 0.6505 |
12:27 ET | 555 | 0.6861 |
12:34 ET | 150 | 0.66845 |
12:39 ET | 174 | 0.652 |
12:57 ET | 200 | 0.6685 |
12:59 ET | 500 | 0.6663 |
01:03 ET | 300 | 0.652 |
01:08 ET | 100 | 0.653 |
01:17 ET | 753 | 0.653 |
01:19 ET | 447 | 0.653 |
01:21 ET | 347 | 0.6531 |
01:30 ET | 100 | 0.6533 |
01:32 ET | 5000 | 0.681614 |
01:46 ET | 219 | 0.6533 |
01:50 ET | 100 | 0.6676 |
01:57 ET | 100 | 0.6535 |
02:00 ET | 225 | 0.6535 |
02:13 ET | 200 | 0.6535 |
02:33 ET | 560 | 0.653601 |
02:38 ET | 100 | 0.6541 |
02:44 ET | 13810 | 0.68 |
02:45 ET | 14267 | 0.68 |
02:58 ET | 200 | 0.68 |
03:00 ET | 100 | 0.6801 |
03:02 ET | 272 | 0.6801 |
03:05 ET | 2601 | 0.68 |
03:07 ET | 3016 | 0.68 |
03:09 ET | 228 | 0.68 |
03:14 ET | 1122 | 0.68 |
03:27 ET | 4190 | 0.6801 |
03:30 ET | 400 | 0.6801 |
03:32 ET | 300 | 0.6801 |
03:36 ET | 100 | 0.68 |
03:41 ET | 100 | 0.6801 |
03:43 ET | 449 | 0.68 |
03:45 ET | 100 | 0.6801 |
03:50 ET | 430 | 0.6849 |
03:56 ET | 100 | 0.6823 |
03:57 ET | 757 | 0.6805 |
03:59 ET | 500 | 0.68 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Equillium Inc | 24.0M | -2.0x | --- |
Microalliance Group Inc | 36.6M | 4.4x | --- |
Biofrontera Inc | 4.3M | -0.1x | --- |
Health-Chem Corp | 1.2K | 0.0x | --- |
Bon Natural Life Ltd | 9.6M | 0.5x | +78.05% |
CASI Pharmaceuticals Inc | 72.5M | -2.4x | --- |
Equillium, Inc. is a clinical-stage biotechnology company. It is engaged in developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The Company’s pipeline consists of immunomodulatory assets and a product platform targeting immuno-inflammatory pathways. The Company’s EQ101 is a selective tri-specific cytokine inhibitor targeting IL-2, IL-9, and IL-15. The EQ302 is an orally delivered, selective bi-specific cytokine inhibitor targeting IL-15 and IL-21. It is in pre-clinical development. Its multi-cytokine platform generates rationally designed composite peptides that selectively block key cytokines at the shared receptor level targeting pathogenic cytokine redundancies and synergies while preserving non-pathogenic signaling. The Itolizumab is a monoclonal antibody that targets the CD6-ALCAM signaling pathway which plays a central role in the modulation of effector T cells.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $24.0M |
---|---|
Revenue (TTM) | $37.9M |
Shares Outstanding | 35.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.82 |
EPS | $-0.35 |
Book Value | $0.64 |
P/E Ratio | -2.0x |
Price/Sales (TTM) | 0.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -34.85% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.